Previous 10 | Next 10 |
Theratechnologies Inc. (THTX) Q2 2022 Earnings Conference Call July 14, 2021, 08:30 AM ET Company Participants Elif McDonald - Senior Director, Investor Relations Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais - SVP &am...
Theratechnologies ( NASDAQ: THTX ) stock rises ~9% after the company announced Q2 result and positive data from its dose escalation portion of Phase 1 study of TH1902 to treat in advanced resistant malignancies. The company tightened it FY2022 revenue guida...
Theratechnologies press release ( NASDAQ: THTX ): Q2 Net loss of $22.73M. Revenue of $19.27M (+8.3% Y/Y) misses by $0.86M . FY2022 revenue guidance tightened to be in the range of $79M - $82M, or growth of the commercial portfolio to be in the range of 13% and 17% ...
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million – Year-to-Date EGRIFTA SV ® Revenue Growth of 21.5% – TH1902 Basket Trial Initiated ...
Confirmed safety profile at 300 mg/m 2 or 1.5 times the therapeutic dose of docetaxel alone Confirmed low levels of free docetaxel consistent with observations in animal studies Early signs of efficacy observed in the dose escalation portion of the study Enrollme...
Theratechnologies ( NASDAQ: THTX ) shares climbed around 5% on Wednesday after the biopharmaceutical company received a binding commitment from an affiliate of Marathon Asset Management for a non-dilutive term loan of up to $100M. Available across multiple tranches, the te...
Financing Will Significantly Strengthen the Balance Sheet and Extend Cash Runway Initial Draw of $40 Million Will Retire $30 Million of the Principal Amount of the Convertible Notes Due in 2023 MONTREAL, July 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“The...
MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN $2 million of funding for a collaborative research project that aims to demonstrate the efficacy and safety of a potential innovative treatment for patien...
MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter...
MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDo...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...